Skip to main content
Fig. 2 | BMC Urology

Fig. 2

From: Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study

Fig. 2

Kaplan–Meier method for the estimation of a overall survival, b progression-free survival, c metastasis-free survival, and d chemotherapy-free survival. PSA Prostate-specific antigen; CI confidence interval

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us